文献速递血液净化与透析急性肾损伤

丙氨酰谷氨酰胺局部免疫代谢干预改善腹膜透析诱导的免疫细胞功能障碍

Local Immunometabolic Intervention With Alanyl-Glutamine Resolves Peritoneal Dialysis-Induced Immune Cell Dysfunction.
PubMed 文献 · Kidney Int Rep · 2026-02-02

这项前瞻性队列研究纳入117例腹膜透析患者(平均随访2.15年),发现腹膜炎症与腹膜细胞免疫功能负相关、与后续腹膜炎风险升高相关(HR 3.8)。代谢组学显示高炎症患者葡萄糖与氨基酸代谢显著扰动,补充丙氨酰谷氨酰胺可特异性恢复高炎症患者的免疫细胞功能。

要点

  • 腹膜炎症与腹膜细胞免疫功能负相关,且与后续腹膜炎风险升高相关(HR 3.8)。
  • 高腹膜炎症患者腹膜代谢组学显示葡萄糖和氨基酸代谢显著扰动。
  • 丙氨酰谷氨酰胺补充可特异性恢复高炎症患者的免疫细胞功能。

核心结论

  • 腹膜炎症与腹膜细胞免疫功能负相关,并与后续腹膜炎风险升高相关(HR 3.8)。
  • 高腹膜炎症患者存在葡萄糖和氨基酸代谢扰动,丙氨酰谷氨酰胺可特异性恢复其免疫细胞功能。

研究设计与样本

  • 前瞻性队列研究纳入117例腹膜透析患者,平均随访2.15年。
  • 对腹膜平衡试验(PET)样本检测IL-6和TLR刺激后细胞因子释放,并对腹膜流出液进行蛋白质组学和靶向代谢组学(1000种代谢物)分析。
  • 采用单中心RCT(n=20)患者流出液与健康供者免疫细胞共孵育实验,并以多中心RCT(n=37)样本作为验证队列。

主要发现

  • 腹膜炎症与腹膜细胞免疫功能呈负相关,与后续腹膜炎风险升高相关(HR 3.8)。
  • 高腹膜炎症患者腹膜代谢组学显示葡萄糖和氨基酸代谢显著扰动。
  • 丙氨酰谷氨酰胺补充可特异性恢复高腹膜炎症患者的免疫细胞功能。

临床怎么用

  • 腹膜炎症标志物(如IL-6)和免疫细胞功能可用于识别高感染风险的腹膜透析患者。
  • 丙氨酰谷氨酰胺补充腹膜透析液可能作为恢复免疫细胞功能、预防腹膜炎的代谢干预策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Peritoneal dialysis (PD) is the most prevalent home-based dialysis therapy. However, chronic exposure to metabolically imbalanced high-glucose PD fluids is associated with infectious complications and morphological changes that limit PD duration and patient survival. Here, we analyzed interactions among peritoneal cell immune function, inflammation, and glucose metabolism in a prospective cohort study of patients on PD. METHODS: In 117 patients (mean follow-up: 2.15 years), samples from peritoneal equilibration tests (PETs) were assessed for interleukin (IL)-6 levels as a measure of peritoneal inflammation, and ex vivo toll-like receptor (TLR)-stimulated cytokine release as a measure of immune cell function. In addition, proteomic profiling and targeted metabolomics (1000 metabolites) were performed on peritoneal effluents. Coincubation experiments using patient effluents from a single-center randomized controlled trial (RCT) (n = 20 patients) and immune cells from healthy donors were also conducted to assess effluent-induced immune modulation. Samples from a multicenter RCT (n = 37 patients) were used as a validation cohort. RESULTS: Peritoneal inflammation correlated negatively with peritoneal cell immune function and positively with increased risk of subsequent peritonitis (hazard ratio: 3.8). Patients with higher peritoneal inflammation had an altered peritoneal metabolomic profile, with significant perturbation of glucose and amino acid metabolism. Immunometabolic intervention with alanyl-glutamine (AlaGln) supplementation of PD fluid restored immune cell function specifically in patients with high peritoneal inflammation, highlighting the potential to prevent subsequent infections. CONCLUSION: These results provide the first direct, longitudinal evidence linking immunometabolism with peritoneal glucose exposure, local inflammation, as well as impaired peritoneal cell function and infection in a human PD cohort. Metabolic intervention designed to restore adequate peritoneal cell immune function represents a novel therapeutic approach with promise for improved clinical outcomes in chronic PD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Herzog R, Daniel-Fischer L, Eibensteiner F, et al. Local Immunometabolic Intervention With Alanyl-Glutamine Resolves Peritoneal Dialysis-Induced Immune Cell Dysfunction. Kidney Int Rep. 2026. PMID: 42006205. doi:10.1016/j.ekir.2026.106342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。